Article Text

PDF
AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan
  1. T. Kojima1,
  2. N. Takahashi1,
  3. A. Kaneko2,
  4. D. Kida2,
  5. Y. Hirano3,
  6. T. Fujibayashi4,
  7. Y. Yabe5,
  8. H. Takagi6,
  9. T. Oguchi7,
  10. H. Miyake8,
  11. T. Kato9,
  12. T. Watanabe10,
  13. M. Hayashi11,
  14. T. Shioura12,
  15. Y. Kanayama13,
  16. K. Funahashi1,
  17. S. Asai1,
  18. Y. Yoshioka1,
  19. K. Terabe1,
  20. T. Takemoto1,
  21. N. Asai1,
  22. N. Ishiguro1
  23. on behalf of Tsurumai Biologics Communication Registry (TBCR)
  1. 1Orthopedic Surgery, Nagoya University Hospital
  2. 2Orthopedic Surgery, Nagoya Medical Center, Nagoya
  3. 3Rheumatology, Toyohashi Municipal Hospital, Toyohashi
  4. 4Orthopedic Surgery, Konan Kosei Hospital, Konan
  5. 5Rheumatology, JCHO Tokyo-Shinjyuku Medical Center, Tokyo
  6. 6Orthopedic Surgery, Nagoya Central Hospital, Nagoya
  7. 7Orthopedic Surgery, Anjo Kosei Hospital, Anjo
  8. 8Orthopedic Surgery, Ichinomiya Municipal Hospital, Ichinomiya
  9. 9Kato Orthopedic Clinic, Okazaki
  10. 10Orthopedic Surgery, Kariya-Toyota General Hospital, Kariya
  11. 11Rheumatology, Nagano Red Cross Hospital, Nagano
  12. 12Orthopedic Surgery, Shizuoka Kosei Hospital, Shizuoka
  13. 13Rheumatology, Toyota Kosei Hospital, Toyota, Japan

Abstract

Background According to Treat to target strategy, we have to consider changing the treatment in 3-6 months. Clinical course of RA treatment should be important to predict further outcome and to decide the therapy management in clinical practice.

Objectives We aimed to identify predictive factors for low disease activity (LDA) achievement and for clinical course to LDA in rheumatoid arthritis (RA) patients switching from tumor necrosis factor inhibitors (TNFis) to abatacept (ABT) with low dose or no methotrexate (MTX) using multicenter Tsurumai Biologics Communication Registry.

Methods From 2,771 RA patients registered in the Tsurumai Biologics Communication Registry until 2013, 76 with moderate or high disease activity who received ABT in switching from TNFis were selected. Relationship between response until 24 weeks and achievement of LDA or remission at 52 weeks was explored using ROC curve. The association of previous TNFis to achievement of LDA or remission at each follow-up period (4-52w) was also determined by adjusting factors at baseline with multivariate logistic regression analyses.

Results Baseline characteristics of study population (n=76) was mean age; 63.4years, disease duration; 13.2 years and baseline DAS28-CRP; 4.90, concomitant MTX use; 52.6% (mean dose; 7.8 mg/week). Previous TNFis were as follows; infliximab (IFX) 14 cases, etanercept (ETN) 41 cases, adalimumab (ADA) 21 cases. DAS28 significantly improved to 3.58 at 52 weeks; 26.3% of patients achieved LDA (Fig.1). DAS28-CRP at 4 and 12 weeks had significant association with LDA at 52 weeks (AUC; 0.74, and 0.86, respectively) while that at baseline did not based on ROC curves (Fig. 2). LDA achievement at 52 weeks was comparable among previous TNFis while there were significant differences in LDA achievement rate and DAS28-CRP at 12weeks by previous TNFis (Fig. 3). Multivariate analysis confirmed that DAS28-CRP<4.0 at 12 weeks was an independent factor (OR: 22.9) for LDA achievement at 52 weeks. Previous etanercept was independent negative factor for LDA achievement at 12w (OR: 0.15), referred to infliximab. Patients who were switched from ETN to ABT could need longer time (more than 24 weeks) for improving than those switched from IFX. Background with low dose or no MTX could cause the production of anti-drug antibody, especially, in IFX and ADA. There is a possibility that switching to ABT could have more effective in bio-switching patients with anti-drug antibody.

Conclusions Clinical course until 12 weeks is important to predict long-term outcome even in switching from TNFi to ABT. The clinical course to LDA achievement could be influenced by previous TNFi.

Disclosure of Interest T. Kojima Grant/research support from: Takeda Pharma Corporation, Janssen Pharmaceutical, and Astellas Pharma Corporation, Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Abbvie, Bristol-Myers Squibb, Pfizer, Chugai Pharma Corporation, Janssen Pharmaceutical, and Astellas Pharma Corporation, N. Takahashi: None declared, A. Kaneko Speakers bureau: Mitsubishi Tanabe Pharma, Takeda Pharma, Eisai Pharma, Chugai Pharma, Abbott, Bristol-Myers Squibb, UCB, Janssen, and Pfizer, D. Kida: None declared, Y. Hirano Speakers bureau: AbbVie Japan, Eisai, Mitsubishi Tanabe Pharma, Pfizer, Chugai Pharmaceutical, and Bristol-Myers Squibb, T. Fujibayashi: None declared, Y. Yabe: None declared, H. Takagi: None declared, T. Oguchi: None declared, H. Miyake: None declared, T. Kato: None declared, T. Watanabe: None declared, M. Hayashi: None declared, T. Shioura: None declared, Y. Kanayama: None declared, K. Funahashi: None declared, S. Asai: None declared, Y. Yoshioka: None declared, K. Terabe: None declared, T. Takemoto: None declared, N. Asai: None declared, N. Ishiguro Grant/research support from: Daiichi Sankyo, Takeda Pharmaceutical, Hisamitsu Pharmaceutical, Otsuka Pharmaceutical, Taisho Toyama Pharmaceutical, Kaken Pharmaceutical, Eisai, Janssen Pharmaceutical, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Astellas Pharma, and Pfizer Japan., Speakers bureau: Daiichi Sankyo, Takeda Pharmaceutical, Hisamitsu Pharmaceutical, Otsuka Pharmaceutical, Taisho Toyama Pharmaceutical, Kaken Pharmaceutical, Eisai, Janssen Pharmaceutical, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical, Mitsubishi Tanabe Pharmaceutical, Astellas Pharma, and Pfizer Japan.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.